Double umbilical cord blood transplant: More than a cell dose?

Leukemia and Lymphoma

Volumn 51, Issue 6, 2010, Pages 975-982

  Stanevsky, Anfisa ^a   Shimoni, Avichai ^a   Yerushalmi, Ronit ^a   Nagler, Arnon ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adults; Cord blood; Double; Expansion; Leukemia; Transplant

Indexed keywords

CD34 ANTIBODY; CYCLOPHOSPHAMIDE; FLUDARABINE;

ACUTE LEUKEMIA; BLOOD DONOR; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CANCER REGRESSION; COMORBIDITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; UMBILICAL CORD; WHOLE BODY RADIATION; ADULT; CHILD; CORD BLOOD STEM CELL TRANSPLANTATION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STEM CELL TRANSPLANTATION; PROCEDURES;

ADULT; CHILD; CORD BLOOD STEM CELL TRANSPLANTATION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING;

EID: 77953530663     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428191003699886     Document Type: Review

References (65)

1. Gluckman E, Broxmeyer HA, Auerbah AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical cord blood from an HLA-identical sibling. N Engl J Med 1989;321:1174-1178.
2. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. New Engl J Med 1997;339:1565-1577.
3. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplantation Group and the European Blood and Marrow Transplantation Group. New Engl J Med 1997;337:373-381.
4. Nitsche A, Zhang M, Clauss T, Siegert W, Brune K, Pahl A. Cytokine profiles of cord and adult blood leukocytes: differences in expression are due to differences in expression and activation of transcription factors. BMC Immunol 2007;31:8-18.
5. Garderet L, Dulphy N, Douay C, et al. The umbilical cord blood alpha beta T-cell repertoire: characteristics of a polyclonal and naive but completely formed repertoire. Blood 1998;91:340-346.
6. Mohty M, Gaugler B. Inflammatory cytokines and dendritic cells in acute graft-versus-host disease after allogeneic stem cell transplantation. Cytokine Growth Factor Rev 2008;19: 53-63.
7. Verneris MR, Miller JS. The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells. Br J Haematol 2009;147:185-191.
8. Dalle JH,Menezes J, Wagner E, et al. Characterization of cord blood natural killer cells: IMPLICATION for transplantation and neonatal infections. Pediatr Res 2005;57:649-655.
9. Condiotti R, Zakai YB, Nagler A. Ex vivo expansion of CD56+cytotoxic cells from human umbilical cord blood. Exp Hematol 2001;29:104-113.
10. Bone Marrow Donors Worldwide. Annual report 2008. Available from: http://www.bmdw.org/uploads/media/BMDW2008. pdf.
11. Sullivan M.J. Banking on cord blood stem cells. Nat Rev Cancer 2008;8:555-563.
12. Rocha V, Gluckman E. Improving outcomes of cord transplantation- related factors. Br J Haematol 2009;147: 262-274.
13. Smith A, Wagner J. Alternative hematopoietic stem cell sources for transplantation: place of umbilical cord blood. Br J Haematol 2009;147:246-261.
14. Wagner J, Barker J, DeFor T, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002;100:1611-1618.
15. Sanz J, Saavedra S, Montesinos P, Sanz G. Unrelated donor umbilical cord blood transplantation (UD-UCBT) for adult patients with high-risk acute myeloid leukemia (AML). Blood 2008;112:4401.
16. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilicalcord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004;351:2276-2285.
17. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcome after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004;351: 2265-2275.
18. Takahashi S, Ooi J, Iseki T, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood 2004;104:3813-3820.
19. Takahashi S, Ooi J, Tomonari A, et al. Comparative singleinstitute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood 2007;109:1322-1330.
20. Rocha V, Eapen M, Scaradavou E, et al. Effect of stem cell source on transplant outcomes in adults with acute leukemia: a comparison of bone marrow, peripheral blood and cord blood. Bone Marrow Transplant 2009;43:S5.
21. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukemia: a comparison study. Lancet 2007;369:1947-1954.
22. Gluckman E, RochaV, EBMT Pediatric, Acute Leukemia Working Parties; Eurocord. Indications and results of cord blood transplant in children with leukemia. Bone Marrow Transplant 2008;41:80-82.
23. US General Accounting Office. Bone marrow transplants: despite recruitment successes, national programs may be underutilized. GAO-03-182. Washington, DC: General Accounting Office; 2002. pp 19-20.
24. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, Wagner JE. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005;105:1343-1347.
25. Tse W, Bunting K, Laughlin M. New insights into cord blood stem cell transplantation. Curr Opin Hematol 2008;15:279-284.
26. Delaney C, Gutman G, Appelbaum F. Cord blood transplantation for hematological malignancies: conditioning regimens, double cord transplant and infectious complications. Br J Haematol 2009;147:207-216.
27. Verneris M, Brunstein C, DeFor T, et al. Risk of relapse after umbilical cord blood transplantation in patients with acute leukemia - marked reduction in recipients of two units. Biol Blood Marrow Transplant 2006;12:1219-1219
28. Brunstein CG, Macmillan ML, Barker J, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft versus leukemia effect in recipients of two units. Blood 2009;114:4293-4299.
29. Willemze R, Rodrigues CA, Labopin M, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia 2009;3:492-500.
30. Sorror ML, Sandmaier BM, Storer BE, et al. Co-morbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol 2007;25:4246-4254.
31. Brunstein CG, Cantero S, Cao Q, et al. Promising progression- free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation. Biol Blood Marrow Transplant 2009; 15:214-222.
32. Matsuno N, Wake A, Uchida N, et al. Impact of HLA disparity in the graft-versus-host direction on engraftment in adult patients receiving reduced-intensity cord blood transplantation. Blood 2009;114:1689-1695.
33. Rocha V, Mohty M, Gluckman E, Rio B. Reduced intensity conditioning regimens before unrelated cord blood transplantation in adults with acute leukemia and other hematological malignancies. Curr Opin Oncol 2009;21(Suppl. 1):S31-S34.
34. Brunstein CG, Barker JN, Weisdorf DJ, et al. Umbilical cord blood transplantation after non myeloablative conditioning: impact on transplantation outcomes in 110 adults with hematological disease. Blood 2007;110:3064-3070.
35. Ballen KK, Spitzer TR, Yeap B, et al. Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Blood 2005;106:579A-580A.
36. Goldstein G, Elhasid R, Bielorai B, et al. Similar engraftment kinetics of cord blood transplantations of double units in adults, versus single unit in children. Bone Marrow Transplant 2009;43:S109-S110.
37. Tamila L, Kindwall-Keller DO, Laughlin M. Prospective phase II study of biologic assignment one versus two unit umbilical cord blood transplant in the reduced intensity conditioning setting. Blood 2008;112:1960.
38. Rodrigues CA, Sanz G, Brunstein CG, et al. Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 2009;27:256-263.
39. Lister J, Gryn JF, McQeen KL. Multiple unit HLAunmatched sex-mismatched umbilical cord blood transplantation for advanced hematological malignancy. Stem Cells Dev 2007;16:177-186.
40. Haspel RL, Kao G, Yeap BY, Ballen KK. Pre infusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant 2008;41:523-529.
41. Frisch BJ, Calvi LM. Hematopoietic niche. Curr Opin Support Palliat Care 2008;2:211-217.
42. Haspel RL, Ballen KK. Double cord blood transplants filling a niche? Stem Cell Rev 2006;2:81-86.
43. Kolet O, Dar A, Lapidot T. The multiple roles of osteoclasts in host defense: bone remodeling and hematopoetic stem cell mobilization. Ann Rev Immunol 2007;25:51-69.
44. Nauta AJ, Kruisselbrink AB, Lurvink E, et al. Enhanced engraftment of umbilical cord blood-derived stem cells in NOD/SCID mice by co transplantation of a second unrelated cord blood unit. Exp Hematol 2005;33:1249-1256.
45. Gutman JA, Turtle CJ, Manley TJ, et al. Single-unit dominance following double unit umbilical cord blood transplantation coincides with a specific CD8+T cell response against the non-engrafted unit. Blood 2010;115:757-765.
46. Avello J, van de Ven C, Fortino W. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering. Biol Blood Marrow Transplant 2006;12:608-622.
47. Miller JS, Brunstein CG, Cooley S. A novel triple umbilical cord blood transplant (UCBT) strategy to promote NK cell immunotherapy (unit 1) with a fully ablative preparative regimen followed by a double UCBT in patients with refractory AML. Blood 2006;108:1403-1403
48. Shpall EJ, Quinones R, Giller R, et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant 2002;8:368-376.
49. Jaroscak J, Goltry K, Smith A, Kurtzberg J. Augmentation of umbilical cord blood (UCB) transplantation with ex vivoexpanded UCB cells: results of a phase 1 trial using the Aastrom Replicell System. Blood 2003;101:5061-5067.
50. de Lima M, McMannis J, Gee A, et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a print phase I/II clinical trial. Bone Marrow Transplant 2008;41:771-778.
51. Bug G, Gül H, Schwarz K, et al. Valproic acid stimulates proliferation and self-renewal of hematopoietic stem cells. Cancer Res 2005;65:2537-2541.
52. Magro E, Regidor C, Cabrera R, et al. Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor. Haematologica 2006;91:640-648.
53. Anker PS, Noort WA, Kruisselbrink AB, Fibbe WE. Non expanded primary lung and bone marrow-derived mesenchymal stem cells promote the engraftment of umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol 2003;31:881-889.
54. Kim DW, Chung YJ, Kim TG, Oh IH. Co-transplantation of third-party mesenchymal stromal cells can alleviate singledonor predominance and increase engraftment from double cord transplantation. Blood 2004;103:1941-1948.
55. Le Blanc K, Samuelsson H, Gustafsson B, et al. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoetic stem cells. Leukemia 2007;21:1733-1738.
56. Resnic I, Shimoni A, Nagler A. Treatment of severe GVHD with mesenchymal stromal cells. Blood 2009;114:2249.
57. Frassoni F, Gualani F, Labopin M, Basigalupo A. Direct intrabone transplant of unrelated cord-blood cells in acute leukemia: a phase I/II study. Lancet Oncol 2008;9:831-839.
58. Frassoni F, Labopin M, Gualani F. Intrabone marrow transplantation of cord blood cells is associated with better platelet recovery and decreased acute GVHD as compared with intravenous transplantation: a Eurocord matched-paired analysis. Bone Marrow Transplant 2009;43:S3.
59. Brunstein CG, Barker JN, Weisdorf DJ, et al. Intra-bone marrow injection to enhance engraftment after myeloablative umbilical cord blood transplantation with two partially HLAmatched units. Bone Marrow Transplant 2009;43:935-940.
60. Calvi LM, Adams GB, Weibrecht N. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425:841-846.
61. Ballen KK, Shpall EJ, Avigan D, Spitzer TR. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biol Blood Marrow Transplant 2007;13:838-843.
62. Perruccio K, Tosti A. Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation. Blood 2005;106:4397-4406.
63. Serrano LM, Pfeiffer T, Olivares S. Differentiation of näve cord blood T cells into CD19-specific cytolytic effectors for post transplantation adoptive immunotherapy. Blood 2006; 107:2643-2652.
64. Nagler A, Volchek Y, Yerushalmi R. Nilotinib treatment postallogeneic stem cell transplantation in advanced (4 CP) chronic myeloid leukemia (CML) and Ph+acute lymphoblastic leukemia (ALL). Blood 2009;114(Suppl. 1):(Abstract 1176).
65. National Institutes of Health. Treatment of imminent haematological relapse in patients with AML and MDS following allogeneic stem cell transplantation with 5-azacitidine (Vidaza1). NCT00422890. Available from: http://clinicaltrials. gov/ct2/show/NCT00422890.